Dystonia is a motor sign characterized by involuntary muscle contractions which produce abnormal postures. Genetic factors contribute significantly to primary dystonia. In comparison, secondary dystonia can be caused by a wide variety of metabolic, structural, infectious, toxic and inflammatory insults to the nervous system. Although classically ascribed to dysfunction of the basal ganglia, studies of diverse animal models have pointed out that dystonia is a network disorder with important contributions from abnormal olivocerebellar signaling. In particular, work with the dystonic (dt) rat has engendered dramatic paradigm shifts in dystonia research. The dt rat manifests generalized dystonia caused by deficiency of the neuronally restricted protein caytaxin. Electrophysiological and biochemical studies have shown that defects at the climbing fiber-Purkinje cell synapse in the dt rat lead to abnormal bursting firing patterns in the cerebellar nuclei, which increases linearly with postnatal age. In a general sense, the dt rat has shown the scientific and clinical communities that dystonia can arise from dysfunctional cerebellar cortex. Furthermore, work with the dt rat has provided evidence that dystonia (1) is a neurodevelopmental network disorder and (2) can be driven by abnormal cerebellar output. In large part, work with other animal models has expanded upon studies in the dt rat and shown that primary dystonia is a multi-nodal network disorder associated with defective sensorimotor integration. In addition, experiments in genetically engineered models have been used to examine the underlying cellular pathologies that drive primary dystonia. This article is part of a Special Issue entitled "Advances in dystonia".
Introduction
It is not possible to envision the field of movement disorders research without animal models. Normal and pathological motor behavior is the final produce of massive neural computations performed by tissues with precise but plastic three-dimensional structures with exacting connectivity patterns. Mammalian models are often essential for evaluating the efficacy of candidate drugs and devices that target specific receptors and/or structures in the brain. Accordingly, in vitro studies are often limited to biochemical and cell biology questions.
The choice of model system (e.g., patients, rodents, primates, in silico, test tube, or cultured neurons) is largely dictated by the particular hypothesis and overall experimental goals. The decision to utilize an animal model should be intimately incorporated with choice 
